EURO-NMSC registry

Dr Marthe Verhaert, medical oncologist at UZ Brussel and AZ Sint-Maria, collaborated with a European consortium to establish the Euro Non-Melanoma Skin Cancer Registry (EURO-NMSC). This initiative arose from the clinical observation that current guidelines for advanced NMSC, particularly CSCC and BCC remain insufficient. Immunotherapy registration trials have historically excluded patients with poor performance status, autoimmune disease or solid organ transplants. Consequently, data on the safety and efficacy of these treatments in frail, elderly or immunosuppressed populations are lacking. The registry systematically collects real-world data on advanced CSCC and BCC across Europe. Its objectives include evaluating treatment outcomes, toxicity profiles, and response durability in routine clinical settings. Additionally, the initiative seeks to improve staging practices, addressing limitations of conventional TNM classification for NMSC. Early findings suggest treatment adaptations may be necessary for geriatric and comorbid cohorts. This multinational effort aspires to generate evidence-based guidance for managing complex NMSC cases in everyday practice.